Quantification and pharmacokinetics of blood-brain barrier disruption in humans
The DOI matches its Crossref record.
Abstract
✓ Hyperosmolar blood-brain barrier disruption (HBBBD), produced by infusion of mannitol into the cerebral arteries, has been used in the treatment of brain tumors to increase drug delivery to tumor and adjacent brain. However, the efficacy of HBBBD in brain tumor therapy has been controversial. The goal of this study was to measure changes in vascular permeability after HBBBD in patients with malignant brain tumors. The permeability (K 1) of tumor and normal brain blood vessels was measured using rubidium-82 and positron emission tomography before and repeatedly at 8- to 15-minute intervals after HBBBD. Eighteen studies were performed in 13 patients, eight with glioblastoma multiforme and five with anaplastic astrocytoma. The HBBBD increased K 1 in all patients. Baseline K 1 values were 2.1 ± 1.4 and 34.1 ± 22.1 µl/minute/ml (± standard deviation) for brain and tumor, respectively. The peak absolute increases in K 1 following HBBBD were 20.8 ± 11.7 and 19.7 ± 10.7 µl/minute/ml for brain and tumor, corresponding to percentage increases of approximately 1000% in brain and approximately 60% in tumor. The halftimes for return of K 1 to near baseline for brain and tumor were 8.1 ± 3.8 and 4.2 ± 1.2 minutes, respectively. Simulations of the effects of HBBBD made using a very simple model with intraarterial methotrexate, which is exemplary of drugs with low permeability, indicate that 1) total exposure of the brain and tumor to methotrexate, as measured by the methotrexate concentration-time integral (or area under the curve), would increase with decreasing infusion duration and would be enhanced by 130% to 200% and by 7% to 16%, respectively, compared to intraarterial infusion of methotrexate alone; and 2) exposure time at concentrations above 1 µM, the minimal concentration required for the effects of methotrexate, would not be enhanced in tumor and would be enhanced by only 10% in brain. Hyperosmolar blood-brain barrier disruption transiently increases delivery of water-soluble compounds to normal brain and brain tumors. Most of the enhancement of exposure results from trapping the drug within the blood-brain barrier, an effect of the very transient alteration of the blood-brain barrier by HBBBD. Delivery is most effective when a drug is administered within 5 to 10 minutes after disruption. However, the increased exposure and exposure time that occur with methotrexate, the permeability of which is among the lowest of the agents currently used clinically, are limited and the disproportionate increase in brain exposure, compared to tumor exposure, may alter the therapeutic index of many drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
“The intracarotid arterial infusion of 2 M concentrations of poorly diffusible solutes such as mannitol causes disruption of the BBB owing to osmotic shrinkage of the endothelial cells.(21) This is associated with severe vasculopathy(22) and chronic neuropathologic changes in rodent models(23) and is also associated wi…”
BackgroundOutwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means
KrolI, R. A., Neuwelt, E. A., & Neuwelt, E. A. (1998) · Neurosurgery · doi:10.1097/00006123-199805000-00082 · Cited by 581
The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery
Groothuis, D. R. (2000) · Neuro-Oncology · doi:10.1093/neuonc/2.1.45 · Cited by 456
Osmotic Opening of the Blood–Brain Barrier: Principles, Mechanism, and Therapeutic Applications
Rapoport, S. I. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1007049806660 · Cited by 428
“Reversibility was confirmed in baboons and in humans, using PET with 82Rb (Zunkeler et al., 1996a, b).”
MethodVolume transmission in the CNS and its relevance for neuropsychopharmacology
Zoli, M. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01343-7 · Cited by 344
Metadata
- Authors
- Zünkeler, B., Carson, R. E., Olson, J., Blasberg, R. G., Devroom, H., Lutz, R. J., Saris, S. C., Wright, D. C., Kammerer, W., Patronas, N. J., Dedrick, R. L., Herscovitch, P., & Oldfield, E. H.
- Venue
- Journal of Neurosurgery
- Published
- 1996-12
- Volume
- 85
- Issue
- 6
- Pages
- 1056-1065
- ISSN
- 0022-3085 (ISSN-L)
- OpenAlex
- W2091850033
- Cited by
- 111
- References
- 0
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantification and pharmacokinetics of blood-brain barrier disruption in humans. https://app.cochat.ai/papers/10.3171/jns.1996.85.6.1056
- The paper
- Zünkeler, B., Carson, R. E., Olson, J., Blasberg, R. G., Devroom, H., Lutz, R. J., Saris, S. C., Wright, D. C., Kammerer, W., Patronas, N. J., Dedrick, R. L., Herscovitch, P., & Oldfield, E. H. (1996). Quantification and pharmacokinetics of blood-brain barrier disruption in humans. Journal of Neurosurgery. https://doi.org/10.3171/jns.1996.85.6.1056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.